Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Panel Rejects Forest Heart Drug

By Drug Discovery Trends Editor | January 18, 2010

WASHINGTON (AP) – Federal health advisers unanimously rejected a new use of Forest Laboratories’ hypertension drug for patients at risk of heart failure.

The Food and Drug Administration’s outside panel of heart specialists voted 8-0 against approving Bystolic to prevent death or hospitalization caused by heart failure, according to an agency spokeswoman.

The FDA is not required to follow the group’s advice, though it usually does.

Forest already markets Bystolic to treat hypertension, or high blood pressure. An additional approval for heart failure would potentially expand the drug’s market to roughly 5.7 million U.S. patients with the disease.

FDA reviewers said in documents issued last week that company data on the new use for Bystolic “lack robustness,” and don’t show a clear advantage for the drug.

New York-based Forest tracked 2,000 elderly patients at risk for heart failure who received either Bystolic or a dummy pill.

The difference in cardiac death and hospitalization due to heart failure between the groups was not statistically significant, according to the FDA.

Agency reviewers also complained that the company made major adjustments to the design of the trial over the course of its four-year timespan.

The FDA also raised questions about whether Forest’s study – which was conducted abroad – was applicable to U.S. medical practice.

Bystolic is a member of the beta blocker family of medications, which are used to help lower dangerously high blood pressure. Forest reported $69.2 million in Bystolic sales for fiscal 2009, according to the company’s annual report.

Competing drugs in the class include generic versions of AstraZeneca’s Toprol and GlaxoSmithKline’s Coreg.

Beta blockers were the fifth most commonly prescribed drug in the U.S. during 2008, with 130 million prescriptions, according to health care research firm IMS Health.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE